New targeted drug shows promise for Hard-to-Treat cancers

NCT ID NCT05639751

Completed Disease control Sponsor: Prelude Therapeutics Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 24 times

Summary

This early-stage study tested a new drug called PRT3789, alone or with chemotherapy (docetaxel), in people with advanced cancers that have a specific change in the SMARCA4 gene. The goal was to find a safe dose and see if the drug shrinks tumors. The study included 135 adults whose cancer had stopped responding to standard treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AdventHealth Medical Group Oncology Research at Celebration

Celebration, Florida, 34747, United States
Centre Leon Berard

Lyon, 69373, France
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Hospital Universitario HM Sanchinarro

Madrid, Madrid, 28050, Spain
Hospital Universitario Vall d'Hebron

Barcelona, 08035, Spain
Institut Gustave Roussy

Villejuif, 94805, France
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

New York, New York, 10016, United States
Leids Universitair Medisch Centrum

Leiden, 2333 ZA, Netherlands
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic, Jacksonville

Jacksonville, Florida, 32224, United States
Mayo Clinic, Rochester

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
NEXT Virginia

Fairfax, Virginia, 22031, United States
National Cancer Centre Singapore

Singapore, Singapore, 168583, Singapore
National University Hospital

Singapore, Singapore, 119074, Singapore
New York Presbyterian Hospital - Columbia University Medical Center

New York, New York, 10032, United States
Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States
Oncopole Claudius Regaud IUCT ONCOPOLE

Toulouse, 31059, France
Providence Cancer Institute Franz Clinic

Portland, Oregon, 97213, United States
START Barcelona - HM Nou Delfos

Barcelona, Barcelona, 08023, Spain
START MADRID - FJD Hospital Universitario Fundacion Jimenez Diaz

Madrid, Madrid, 28040, Spain
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21287, United States
Smilow Cancer Hospital Phase 1 Unit

New Haven, Connecticut, 06511, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
UCLA Hematology/Oncology - Santa Monica

Santa Monica, California, 90404, United States
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of California, Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
Washington University School of Medicine - Siteman Cancer Center

St Louis, Missouri, 63110, United States
Winship Cancer Institute

Atlanta, Georgia, 30322, United States
lnstitut Bergonie Centre Regionale de Lutte Contre le cancer, Service Oncologie-Medicale

Bordeaux, 33000, France
lnstitut Paoli Calmettes

Marseille, 13009, France

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR NON-SMALL CELL LUNG CANCERS NON-SMALL CELL LUNG CANCERS SMARCA4 GENE MUTATION